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Anti-tumoral endoscopic ultrasound-guided ﬁne-needle injection (EUS-FNI), with its minimally invasive access for anti-tumoral agent delivery, is the
most exciting ﬁeld of intervention EUS. Pancreatic cancer is regarded as a systemic disease even if imaging modalities reveal no visible metastasis. From
that perspective, immunological therapy is performed. To date, several reports have described immunotherapy under EUS-guidance. The ﬁrst report of
EUS-FNI intended for immunotherapy for advanced pancreatic cancer was published in 2000. In that study, an allogeneic mixed-lymphocyte culture was
injected into tumors of eight patients with unresectable local pancreatic adenocarcinoma. The study of dendritic cells (DCs) for cancer has continued to
develop in recent years. Actually, DCs are potent antigen-presenting cells for the induction of primary T-cell dependent immune response. When injected
intratumorally, DCs acquire and process tumor antigens in situ, migrate to regional lymphoid organs, and initiate a strong tumor-speciﬁc immune
response. To date, three reports have described EUS-FNI of DCs into pancreatic cancer: two for unresectable and one for pre-surgical operations. Every
study has indicated the feasibility and safety. Furthermore, these reports showed that EUS-guided DCs injection might be an important option for treating
advanced pancreatic cancer. EUS-guided immunotherapy is a very exciting ﬁeld in interventional EUS for obstinate cancers.
Copyright  2014, Society of Gastrointestinal Intervention. Published by Elsevier.
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Pancreatic cancer is among the most lethal cancers because of
its attendant difﬁculty in early diagnosis and its resistance to
standard treatments such as surgical resection, radiation, and
chemotherapy. Pancreatic cancer, which entails high mortality in
the United States and European countries, is the ﬁfth leading cause
of cancer deaths among men and sixth among women in Japan.
With 5-year survival of less than 10%, it is themajor leading cause of
cancer-related death in the world.1 Therefore, new therapeutic
methods are required as an urgent issue.
Interventional endoscopic ultrasound (EUS) is widely per-
formed not only for tissue diagnosis but also for treatment in pa-
tients with abnormalities of various organs. Treatment using EUS-
guided ﬁne-needle injection (EUS-FNI) has expanded the clinical
utility of EUS.2–7 Antitumoral EUS-FNI, with its minimally invasive
access for antitumoral agent delivery, is the most exciting ﬁeld of
interventional EUS today. Several applications of EUS-FNI for anti-
cancer efforts have included drug delivery into the tumors, such as
ablation using ethanol, chemotherapy, gene therapy, and cytoim-
plantation. These procedures are divisible onto three categories
based on the associated therapeutic mechanisms: physicochemical
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cancer in 2000, various antitumoral agents have been injected
directly into tumors.7–14 Recently, several immunotherapies using
EUS have been performed using the beneﬁts of EUS guidance:
minimally invasive, direct access, and high resolution. As described
in this paper, we reviewed EUS-guided oncologic immunotherapy
for pancreatic cancer.
Details of EUS-guided immunotherapy
Pancreatic cancer is regarded as a systemic disease even if im-
agingmodalities reveal no visible metastasis. From this perspective,
immunological therapy is performed. To date, four reports in the
relevant literature have described immunotherapy under EUS
guidance. In particular, EUS-FNI using dendritic cells (DCs) is a
promising procedure as immunotherapy for cancers (Table 1).
Allogenic mixed lymphocyte culture
Chang et al8 injected cytoimplants directly into pancreatic
cancer and evaluated its technical feasibility and safety in 2000.
They used allogeneic mixed lymphocyte cultures (cytoimplants).
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Table 1 Published Data on EUS-guided Immunotherapy using Dendritic Cells
Author No. of
patients
Disease Indication Combination
therapy
Success rate
of EUS-FNI
Efﬁcacy/prognosis Complications
Irisawa
et al 200712
7 Unresectable pancreatic
cancer with metastasis
Refractory to intravenous
gemcitabine
None 100% 2 mixed response,
2 stable disease >6 mo.
Median survival was 9.9 mo.
No severe event
Hirooka
et al 200920
5 Unresectable locally
advanced pancreatic
causer
First line treatment Intravenous
gemcitabina
100% 1 partial remission,
2 stable disease >6 mo.
No severe event
Endo
et al 201221
9 Unresectable pancreatic
cancer
Prior to surgery Surgery 100% 1 patient (stage IV) with distant
lymph node metastasis
survived >6 mo.
No severe event
EUS-FNI, endoscopic ultrasound ﬁne-needle injection.
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release of cytokines and the activation of immune effector cells. In
this clinical trial, eight patients with unresectable pancreatic cancer
received EUS-guided injections of cytoimplant. The ﬁrst two pa-
tients received 3 billion cells, the next three patients received 6
billion cells, and the last three patients received 9 billion cells.
Results showed two partial responses and one minor response,
with a median survival of 13.2 months. No procedure-related
complication occurred. The study demonstrated the possibilities
of EUS-FNI based on immunotherapy for unresectable pancreatic
cancer. Unfortunately, no active clinical protocol has existed to
evaluate cytoimplants for pancreatic cancer for more than 10 years.Immature DCs for unresectable pancreatic cancer
Immunotherapy is a novel approach that has been investigated
using different types of tumors including pancreatic cancer. During
the past 2 decades, adoptive immunotherapy based on tumor-
inﬁltrating lymphocytes or lymphokine-activated killer (LAK)
cells has been used in clinical trials.15,16 These early results provided
the ﬁrst evidence that the manipulation of the immune system
represents a promising tool in cancer immunotherapy. Further-
more, Steinman et al17 discovered the crucial role of DCs for the
induction of primary T cell-dependent immune responses. DCs are
now regarded as the best adjuvant for antitumor immunity.
The ﬁrst results for an animal model of pancreatic cancer were
reported in 2002 by Akiyama et al.18 They demonstrated that tumor
growth was signiﬁcantly inhibited by 82% in hamsters treated (sub-
cutaneous injection) using DCs pulsed with tumor lysate and N[1-
(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate,
and suggested that DC-based immunotherapy might be a useful
approach for the treatment of pancreatic cancers. Techniques of
interventional EUS permit direct intratumoral injection of DCs.
Intratumorally injected DCs would acquire and process tumor anti-
gens in situ, migrate to regional lymphoid organs via lymphoid ves-
sels, and initiate a signiﬁcant tumor speciﬁc immune response. In
addition,DCshave antigen-capturingabilities andprocessingabilities
as well as trafﬁcking abilities only during their immature phase.19
Based on this background, the author performed EUS-FNI of
immature DCs into unresectable pancreatic cancer in seven pa-
tients with prior chemotherapy (e.g., gemcitabine) failure.12
Immature DCs were generated by the patients’ peripheral blood
mononuclear cells after stimulation with granulocyte–macrophage
colony-stimulating factor and interleukin 4. The patients received
intratumoral injections of 10 billion or more immature DCs at two
to three sites using EUS-FNI. Five of the seven patients underwent
irradiation prior to the initial DC injection to facilitate tumor-
associated antigens for DC cross-presentation. DC was adminis-
tered on Day 1, Day 8, and Day 15. The cycles were repeated every
28 days to the greatest extent possible. All DC injections were
tolerated, with no clinical toxicity. No complication associated withthe procedure was noted. The median patient survival was 9.9
months in spite of being refractory to gemcitabine. Results show
that intratumoral injection of unpulsed DCs into the pancreatic
cancer using EUS-FNI is safe, and that it can induce some clinical
responses in patients with advanced diseases. Later, Hirooka et al20
reported the results of a combination therapy of gemcitabine with
immunotherapy for patients with inoperable, locally advanced
pancreatic cancer. Five patients received the treatment course,
which consisted of an intravenous gemcitabine administration at
1000 mg/m (Day 1) and the EUS-FNI of OK432-pulsed DCs into a
tumor, with subsequent intravenous infusion of LAK cells stimu-
lated with anti-CD3 monoclonal antibody (CD3-LAKs; Day 4), at 2-
week intervals. Results showed no severe treatment-related
adverse events. Moreover, three of the ﬁve patients demonstrated
effective responses to this clinical trial: one patient had partial
remission; and two patients had long stable disease lasting longer
than 6 months. In the patient with partial remission, results
demonstrated that DC-based vaccination combined with gemcita-
bine administration induces tumor antigen-speciﬁc cytotoxic T
lymphocytes. Consequently, they concluded that the combined
therapy is to be regarded as synergistically effective and that it
might have a role in the therapy of pancreatic cancer for inducing
tumor antigen-speciﬁc cytotoxic T lymphocytes.Immature DCs for resectable pancreatic cancer as neoadjuvant therapy
Recently, Endo et al21 reported the feasibility and safety of EUS-
FNI using immature DCs with OK-432 into resectable pancreatic
cancer prior to the surgical operation as neoadjuvant therapy. Nine
patients enrolled in this trial (DC group) were compared with 15
patients who had undergone the operation without immature DC
injection (non-DC group). The authors evaluated not only the
clinical utility but also the histological changes within the tumor
and lymph nodes by immunohistochemical examination of inﬁl-
trating inﬂammatory cells (CD4þ, CD8þ, Foxp3þ, and CD83þ). The
authors reported that two patients, one of whomwas stage IV with
distant lymph nodemetastasis, had remarkably survivedmore than
5 years without requiring adjuvant therapy. Additionally, they
showed that CD83þ cells had accumulated signiﬁcantly in the
regional lymph nodes of the DCs injection group as well as Foxp3þ
cells in the regional and distant lymph nodes in comparison with
the no DCs injection group. EUS-FNI of immature DCs as neo-
adjuvant therapy might be useful for improved prognosis in pa-
tients with resectable pancreatic cancer.
Conclusion
EUS-guided intervention has opened new and exciting clinical
applications for the management of malignancies. In particular,
EUS-guided immunotherapy is an exciting ﬁeld in interventional
EUS for obstinate cancers. For greater development in this ﬁeld, it is
Gastrointestinal Intervention 2014 3(1), 24–2626anticipated that endosonographers, basic scientists, and engineers
will collaborate fruitfully with much greater mutual effort. Once an
effective therapy becomes available, it is likely to become impor-
tant for cancer treatment. This effort remains a work in progress.
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